Pharma Manufacturing & Marketing - 2026: The edition has been prepared after being closely scrutinized by a distinguished panel of judges including CXOs, analysts, and our editorial board. We recognize their valuable contribution to the ever expanding and competitive market and their ability to sustain themselves and emerge as top contestants through their reliable products.
"By carefully studying local healthcare requirements and adapting commercial strategies to individual markets, the company has developed a business model that balances accessibility with long-term competitiveness" - SKS LABORATORIES
"Nature's Global Service has invested significantly in quality assurance by establishing in-house testing capabilities supported by a dedicated Radiation Safety Officer (RSO)" - NATURE'S GLOBAL SERVICE
"POSITROSCINT is playing an important role in strengthening India's molecular imaging ecosystem while supporting hospitals and clinicians in delivering timely and accurate cancer diagnosis" - POSITROSCINT
Let's delve more into these prominent players and know how they are spearheading the industry today.
Our subscribers play a decisive role in finalization of our annual list of Pharma Manufacturing & Marketing - 2026 by nominating those which have served them with excellence and are praiseworthy. If you feel there is a company that deserves to be on our annual list, do write to us about them mentioning their value proposition.
 |  | SKS Laboratories | The pharmaceutical anti-infectives segment remains one of the most indispensable pillars of modern healthcare. Even as medical science advances and healthcare systems become increasingly sophisticated, infectious diseases continue to pose significant public health challenges across developed and emerging economies alike. |
 |  | Nature's Global Service | The growing adoption of diagnostic imaging, image-guided interventions, and minimally invasive procedures has elevated radiation protection from a regulatory requirement to a critical element of healthcare safety. |
 |  | POSITROSCINT | The evolution of cancer diagnostics is increasingly being driven by molecular imaging technologies that enable clinicians to detect diseases at earlier stages and make more informed treatment decisions. |
